Icr hosts sab biotherapeutics ceo eddie sullivan on the welcome to the arena podcast

New york--(business wire)--icr, a leading strategic communications and advisory firm, is pleased to announce that eddie sullivan, phd, co-founder, president and ceo of sab biotherapeutics (nasdaq: sabs), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, high-avidity, fully-human polyclonal antibodies without the need for human donors, recently appeared on episode 67 of icr’s “welcome to the arena” podcast. welcome to the arena is hosted by tom ryan, co-founder & ceo of icr. tom spoke with eddie about sab's polyclonal antibody research and their unique use of cows, the future of fighting diseases, the biggest challenges in biotech, and more. the welcome to the arena podcast has featured discussions with ceos, cfos, financial analysts, members of the media, investment bankers, private equity executives and others who influence and create value for public and private-equity backed companies. the podcast made its debut in august 2021, airing episodes roughly every two weeks, and is available on apple podcasts, spotify, google podcasts, or anywhere else you get your podcasts. about icr established in 1998, icr partners with its clients to execute strategic communications and advisory programs that achieve business goals, build awareness and credibility, and enhance long-term enterprise value. the firm’s highly-differentiated service model, which pairs capital markets veterans with senior communications professionals, brings deep sector knowledge and relationships to approximately 1,000 clients across more than 20 industry groups. icr’s healthcare practice operates under the westwicke brand (www.westwicke.com). today, icr is one of the largest and most experienced independent communications and advisory firms in north america, maintaining offices in new york, norwalk, boston, baltimore and beijing. learn more at www.icrinc.com. follow us on twitter at @icrpr.
SABS Ratings Summary
SABS Quant Ranking